CIBC Asset Management Inc Acquires 111 Shares of Natera, Inc. (NASDAQ:NTRA)

CIBC Asset Management Inc grew its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 3.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,477 shares of the medical research company’s stock after acquiring an additional 111 shares during the period. CIBC Asset Management Inc’s holdings in Natera were worth $441,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the stock. SG Americas Securities LLC grew its stake in Natera by 1,073.1% during the second quarter. SG Americas Securities LLC now owns 65,730 shares of the medical research company’s stock valued at $7,118,000 after acquiring an additional 60,127 shares in the last quarter. Chartwell Investment Partners LLC increased its holdings in shares of Natera by 37.9% in the third quarter. Chartwell Investment Partners LLC now owns 41,302 shares of the medical research company’s stock worth $5,243,000 after purchasing an additional 11,362 shares during the period. Natixis purchased a new stake in shares of Natera in the first quarter worth $758,000. Baader Bank Aktiengesellschaft bought a new stake in Natera during the second quarter valued at $478,000. Finally, Virtu Financial LLC bought a new stake in Natera during the first quarter valued at $707,000. 99.90% of the stock is owned by institutional investors.

Insider Activity at Natera

In other Natera news, Director Rowan E. Chapman sold 2,614 shares of Natera stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $127.68, for a total transaction of $333,755.52. Following the transaction, the director now owns 7,969 shares of the company’s stock, valued at $1,017,481.92. The trade was a 24.70 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Steven Leonard Chapman sold 5,024 shares of the company’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $128.48, for a total transaction of $645,483.52. Following the completion of the sale, the chief executive officer now directly owns 195,686 shares of the company’s stock, valued at $25,141,737.28. The trade was a 2.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 46,503 shares of company stock valued at $6,325,804 over the last 90 days. 7.60% of the stock is owned by corporate insiders.

Natera Trading Up 0.8 %

Shares of NTRA stock opened at $169.20 on Friday. The stock’s fifty day moving average is $129.84 and its two-hundred day moving average is $117.00. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The firm has a market capitalization of $22.34 billion, a P/E ratio of -96.23 and a beta of 1.53. Natera, Inc. has a fifty-two week low of $53.62 and a fifty-two week high of $171.95.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.31. The firm had revenue of $439.80 million for the quarter, compared to analyst estimates of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business’s revenue for the quarter was up 63.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.95) EPS. Research analysts expect that Natera, Inc. will post -1.66 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. StockNews.com lowered Natera from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. TD Cowen lifted their target price on shares of Natera from $155.00 to $175.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. The Goldman Sachs Group increased their price target on shares of Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a report on Wednesday, October 16th. JPMorgan Chase & Co. lifted their price objective on shares of Natera from $135.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday, November 13th. Finally, Robert W. Baird upped their target price on shares of Natera from $120.00 to $160.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating and seventeen have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $140.59.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.